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Abstract
 
CD4
 
  
 
T cells play an important role in orchestrating host immune responses against cancer,
particularly by providing critical help for priming and extending the survival of CD8
 
  
 
T cells.
However, relatively little is known about major histocompatibility complex class II–restricted
human tumor antigens capable of activating CD4
 
  
 
T cells. Here, we describe the identification
of a mutated fibronectin (FN) as a tumor antigen recognized by human histocompatibility leu-
 
kocyte antigen-DR2–restricted CD4
 
  
 
T cells. Deoxyribonucleic acid (DNA) sequencing
analysis indicated that this gene contains a mutation that results in the substitution of lysine for
glutamic acid and gives rise to a new T cell epitope recognized by CD4
 
  
 
T cells. Tumor cells
harboring the mutant FN resulted in the loss of FN matrix formation and the gain of metastatic
potential based on the migration pattern compared with that of tumor cells that express wild-
type FN. Additional experiments using cell lines stably expressing the mutated FN cDNA
demonstrated that the point mutation in FN was responsible for the loss of FN staining in ex-
tracellular matrices and the enhancement of tumor cell migration. These findings represent the
first demonstration that a mutated gene product recognized by CD4
 
  
 
T cells is directly in-
volved in tumor metastasis, which indicates the importance of CD4
 
  
 
T cells in controlling the
spread of tumor cells to distant anatomic sites.
Key words: cancer vaccines • cancer biology • CD4
 
  
 
T cells • antitumor immunity • 
immunotherapy 
 
Introduction
 
Cancer cells are derived from a cell with accumulated ge-
netic mutations or alterations that make them more immu-
nogenic than normal cells. Although a number of tumor
antigens recognized by CD8
 
  
 
T cells have been identified
in melanomas as well as other types of cancers, the majority
of these class I–restricted antigens are nonmutated self-pro-
 
teins (1–3). Few mutated antigens, including CDK4, 
 
 
 
-cate-
nin, and caspase 8, have been identified and implicated in
the involvement of cell cycle regulation, tumorigenesis, or
apoptosis (4–6). To facilitate the identification of MHC
class II–restricted antigens, we recently developed a novel
genetic approach to cloning the genes encoding MHC class
II–restricted tumor antigens (7). Three class II–restricted
tumor antigens were successfully identified by this method:
fusion protein LDFP (LDLR and FUT fusion protein) re-
sulting from chromosomal rearrangement, and the mutated
antigens CDC27 and triosephosphate isomerase, of which
the latter is being independently identified by a biochemi-
cal approach (7–9). Of particular interest, the mutated hu-
man CDC27 protein, an important component of an
anaphase-promoting complex involved in cell cycle regula-
tion, could give rise to a melanoma target antigen, al-
though the point mutation itself does not constitute a T
cell epitope. Instead, the missense mutation in a putative
phosphorylation site allows a nonmutated peptide within
CDC27 to be presented to T cells by MHC class II mole-
 
H. Wang and J. Zhou contributed equally to this work.
Address correspondence to Rong-Fu Wang, The Center for Cell and
Gene Therapy and Department of Immunology, Baylor College of Medi-
cine, ALKEK Building N1120, One Baylor Plaza, Houston, TX 77030.
Phone: 713-798-1244; Fax: 713-798-1263; E-mail: rongfuw@bcm.tmc.edu 
1398
 
Role of a Mutated Fibronectin in ECM Formation and Metastasis
 
cules (7). Indeed, the majority of MHC class II–restricted
tumor antigens currently identified with the use of tumor-
reactive T cells are mutated or fusion proteins and there-
fore may represent immunogenic targets recognized by
CD4
 
  
 
T cells.
The biological functions of the mutated antigens identi-
fied by tumor-reactive CD4
 
  
 
and CD8
 
  
 
T cells suggest
that these mutated gene products not only contribute to tu-
mor development, but also to tumor metastasis and pro-
gression. Although melanoma is a highly invasive skin can-
cer, few genetic mutations have been linked to its
biological behavior. It is widely accepted that after the on-
set of oncogenesis, tumor cells with metastatic potential
migrate away from the primary tumor, and invade and im-
plant in distant sites where they reestablish tumor growth
(10). Gene products involved in the formation of extracel-
lular matrix (ECM),
 
* 
 
including fibronectin (FN), have
been implicated in tumorigenesis and metastasis (11–13),
but so far no direct evidence for this association has been
reported (10).
Here we describe the identification and characterization
of mutant FN as a class II–restricted tumor antigen recog-
nized by tumor-reactive CD4
 
  
 
T cells derived from a mel-
anoma patient. A point mutation resulted in the substi-
tution of a Lys (positively charged) for Glu (negatively
charged) residue in FN, giving rise to an epitope for T cell
recognition. Importantly, we found that the mutation in
FN was directly responsible for the loss of FN matrix for-
mation, leading to the enhanced migration of tumor cells.
Thus, the identification of such MHC class II–restricted tu-
mor antigens not only provides potentially important im-
mune targets for effective cancer immunotherapy, but also
improves understanding of the mechanisms by which these
antigens participate in tumor development and metastasis.
 
Materials and Methods
 
Chemicals and Reagents.
 
The following chemicals and re-
agents were used: RPMI 1640, AIM-V medium, Lipofectamine,
and G418 (GIBCO BRL); the eukaryotic expression vector
pcDNA3.1 (Invitrogen); anti–HLA-DR2 mAb (One Lambda);
and anti-immunoglobulin mAb conjugated with fluorescent
isothiocyanate (Vector Laboratories).
 
Cell Lines and Cultures.
 
CD4
 
  
 
F27 tumor-infiltrating lym-
phocytes (TIL) were cultured from a subcutaneous metastasis ob-
tained from a melanoma patient by fine needle aspiration. T cell
clones or lines were grown in AIM-V medium containing 10%
human AB serum and recombinant IL-2 (6,000 IU/ml; Chiron
Corp.). Melanoma cell lines and EBV-transformed B cell lines
were maintained in RPMI 1640 with 10% FCS. 293IMDR2
cells were grown in DMEM containing 10% FCS. The T cell
clones were generated by limiting dilution methods (one cell/
well) from the CD4
 
  
 
F27TIL cell line, and feeder allogeneic PBMCs
in RPMI 1640 containing 10% human AB serum and 300 IU IL-2.
To obtain optimal expansion, we used the OKT3 expansion
method as previously described (14, 15). Melanoma cell lines and
 
EBV-transformed B cell lines were cultured in RPMI 1640 me-
dium containing 10% FCS. 293IMDR2 cells were established by
transfecting plasmid DNA encoding DRB1*1501 cDNA into
293IMA cells expressing the Ii, DMA, DMB, and DRA genes,
and selected with RPMI 1640/10% FCS containing blasticidin S
(25 
 
 
 
g/ml). HLA-DR2–positive cells were sorted by FACS
 
® 
 
us-
ing DR2-specific Abs.
 
cDNA Library Construction.
 
Total RNA was extracted from
F27mel cells using Trizol reagent (GIBCO BRL). PolyA RNA
was purified from total RNA by the polyATract system
(Promega) and converted to cDNA using a cDNA construction
kit (GIBCO BRL) with an oligo-dT primer. The cDNA inserts
were then ligated to a pTSX vector containing an Ii fragment
(amino acid 1–80) (7), and cDNA libraries were electroporated
into DH10B cells (GIBCO BRL). Plasmid DNA for cDNA li-
brary pools was prepared from bacteria, each consisting of 
 
 
 
100
cDNA clones.
 
cDNA Library Screening and GM-CSF Secretion Assay.
 
DNA
transfection and GM-CSF assays were performed as previously
described (7, 8). In brief, 200 ng cDNA pools were mixed with 2
 
 
 
l lipofectamine in 100 
 
 
 
l serum-free DMEM for 15–45 min.
The DNA–lipofectamine mixture was then added to the
293IMDR2 cells (5 
 
  
 
10
 
4
 
) and incubated overnight. The next
day, cells were washed twice with AIM-V medium. CD4
 
  
 
T
cells were then added at a concentration of 5 
 
  
 
10
 
4
 
 cells/well in
AIM-V medium containing 120 IU/ml IL-2. After 18–24 h of
incubation, 100 
 
 
 
l supernatant was collected and GM-CSF con-
centrations were measured in a standard ELISA assay (R&D Sys-
tems). To test peptide recognition, 888EBV were incubated with
peptides at 37
 
 
 
C for 90 min and then washed three times with
AIM-V medium containing 120 IU/ml IL-2. T cells were added
and incubated for an additional 18–24 h.
 
Northern Blot Analysis.
 
Total RNA from human normal tis-
sue was purchased from CLONTECH Laboratories, Inc. 20 
 
 
 
g
total RNA was subjected to electrophoresis in a 1.2% formalde-
hyde agarose gel and transferred to a nylon membrane. DNA
fragments of the FN gene were labeled with [
 
 
 
-
 
32
 
P]dCTP by the
random priming method. Prehybridization and hybridization
were performed according to the QuickHyb protocol (Strat-
agene). Membranes were washed twice with 2
 
  
 
SSC/0.1% SDS
at room temperature for 15 min and twice with 0.1
 
  
 
SSC/0.1%
SDS at 60
 
 
 
C for 30 min. Autoradiography was performed at
 
 
 
70
 
 
 
C. An actin probe was used to serve as the internal control
for the amount of total RNA loading onto the gel.
 
Peptide Synthesis and T Cell Epitopes.
 
The peptides were syn-
thesized by a solid phase method using a peptide synthesizer
(model AMS 422; Gilson Co.). Some peptides were purified by
HPLC and had 
 
 
 
98% purity. The mass of some peptides was
confirmed by mass spectrometry analysis. Peptides reactive with
CD4
 
  
 
F27TIL-T1 cells were identified and characterized as pre-
viously described (7, 8).
 
Cloning of Full-length FN cDNA.
 
A SuperScript II reverse
transcription kit (Invitrogen) was used. 20 
 
 
 
l reverse transcription
mixture contained 2 
 
 
 
g total RNA and was incubated at 42
 
 
 
C
for 1 h. After reverse transcription, 2.5 
 
 
 
l reverse transcription
mixture was used in PCR. 50 
 
 
 
l PCR reaction mixture con-
tained 5 
 
 
 
l 10
 
  
 
ThermalAce buffer, 1 
 
 
 
l 50
 
 
 
 dNTP mixture,
200 
 
 
 
M primer FN5P2 (5
 
  
 
CTCAACATGGTTAGGGGTC-
CGGGGCCCGGGCTG), 200 
 
 
 
M primer FN3P1 (5
 
 
 
AGAGACATGCTTGTTCCTCTGGA), and 2 
 
 
 
l ThermalAce
DNA polymerase (Invitrogen). Primer FN5P2 is a sense primer
that corresponds to the 5
 
 
 
-end sequence of the FN gene. Primer
FN3P1 is an antisense primer that corresponds to the 3
 
 
 
-end se-
 
*
 
Abbreviations used in this paper:
 
 ECM, extracellular matrix; FN, fibronec-
tin; TIL, tumor-infiltrating lymphocytes. 
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quence of the FN gene. The PCR amplification program in-
cluded an initial step of 2 min at 95
 
 
 
C, 30 cycles of 30 s at 95
 
 
 
C,
30 s at 65
 
 
 
C, 10 min at 72
 
 
 
C, and a final step of 15 min at 72
 
 
 
C.
50 
 
 
 
l PCR product was then supplemented with 1 
 
 
 
l Taq DNA
polymerase (Invitrogen) and incubated at 72
 
 
 
C for 30 min. 50 
 
 
 
l
PCR product was separated on a 0.8% (wt/vol) agarose gel. The
desired bands of PCR product was gel purified and then cloned
into pCR-XL-TOPO vector (Invitrogen). Individual plasmid
DNAs were prepared and sequenced to confirm the correctness
of full-length wild-type and point-mutated FN cDNAs.
 
Transfection of FN Genes into Tumor Cells.
 
Both wild-type and
mutated FN gene fragments were released with Hind III and
NotI from the pCR-XL-TOPO vector and subcloned into a
pcDNA3.1/zeocin vector (Invitrogen). Plasmid DNAs encoding
either wild-type or mutated FN cDNA, as well as a pcDNA3.1/
zeocin empty vector, were transfected into 1143mel tumor cells
in six-well plates with lipofectAMINE (GIBCO BRL). Trans-
fected tumor cells were selected in RPMI 1640/10% FCS con-
taining 250 
 
 
 
g/ml zeocin (Invitrogen).
 
Immunostaining of ECM with Anti-FN Ab.
 
1143mel, 1195mel,
F27mel, and FN-transfected tumor cells were cultured overnight
in six-well plates containing a coverslip. Cells attached to the
coverslips were fixed in PBS/4% formaldehyde at room tempera-
ture for 20 min and washed three times with PBS. The coverslips
were kept in acetone at 
 
 
 
20
 
 
 
C for 3 min, air-dried, and washed
three times with PBS. They were then blocked in PBS/5% FCS
in a moist chamber at 37
 
 
 
C for 20 min, washed with PBS for 5
min, and incubated with 1:500 anti-FN mAb (Ab-9; NeoMark-
ers) in a moist chamber at 37
 
 
 
C for 1 h. Similar experiments with
other anti-FN Abs (Ab-1, Ab-7, Ab-8, and Ab-9; NeoMarkers)
were also performed. The slides were washed three times with
PBS, blocked with PBS/5% FCS at room temperature for 20
min, washed two times with PBS, incubated with 1:20 Texas
red–conjugated anti–mouse IgG in the dark in a moist chamber at
37
 
 
 
C for 30 min, and then washed five times with PBS. They
were kept in PBS overnight at 4
 
 
 
C, mounted in PBS/50% glyc-
erol, viewed with a fluorescence microscope, and photographed
at 
 
 
 
40.
 
Migration Assays.
 
2.5 
 
  
 
10
 
4
 
 1143mel and transfected tumor
cells were seeded into the upper chamber with 0.75 ml RPMI
1640 serum-free medium in Biocoat Matrigel cells (Becton Dick-
inson). The bottom chamber contained 0.75 ml RPMI 1640 se-
rum-free medium (control medium) or 0.75 ml RPMI 1640/
10% FCS (complete medium). After incubation at 37
 
 
 
C with 5%
CO
 
2
 
 for 48 h, cells in the lower chambers were fixed in 4%
formaldehyde in PBS at room temperature for 20 min, stained
with crystal violet, and examined and counted from four different
fields under a compound microscope.
 
Immunoprecipitation and Western Blotting.
 
1143mel, 1195mel,
and F27 were lysed in lysis buffer on ice. After spinning, the cell
lysates were immunoprecipitated with an anti-
 
 
 
1 integrin Ab
and pulled down with protein A beads. The immunoprecipitated
complexes were separated on SDS-PAGE. After membrane
transfer, proteins were detected with anti-FN or anti-
 
 
 
1 integrin
Abs. For the detection of FN in whole cell lysates, 1143mel,
1195mel, and F27mel tumor cells from T75 flasks with 80–90%
confluence were trypsinized. After spinning, the cell pellets were
collected and redissolved in SDS loading buffer (50 mM Tris-
HCl, pH 6.8, 100 mM DTT, 2% SDS, and 10% glycerol). The
protein concentration was determined with Bio-Rad protein as-
say dye reagent (Bio-Rad Laboratories). 15 
 
 
 
g total protein for
each sample was loaded onto an 8% SDS polyacrylamide gel,
separated at 100 V constant for 1 h, and transblotted onto a ni-
trocellulose membrane (BA83; Schleicher & Schuell) at a con-
stant 100 V for 1 h. The membrane was blocked with 3% milk
for 1 h, incubated with 1:200 anti-FN mAb for 1 h, and washed
three times with TBST (10 mM Tris-HCl, pH 8.0, 150 mM
NaCl, and 0.05% Tween-20) for 5 min. The membrane was in-
cubated with 1:3,000 goat anti–mouse horseradish peroxidase–
conjugated IgG for 1 h, washed three times with TBST for 5
min, rinsed with water, detected with LumiGLO chemilumines-
cent substrate (Kirkegaard & Perry Laboratories), exposed to
X-OMAT AR film (Eastman Kodak Co.), developed automati-
cally, and photographed.
 
Results
 
Recognition of Autologous Tumor Cells by HLA-DR2–
restricted CD4
 
  
 
T Cells.
 
In a search for tumor-reactive
CD4
 
  
 
T cells, we recently established four CD4
 
  
 
T cell
clones from F27TIL cells. They recognized the autologous
tumor cell line F27mel, but did not respond to autologous
PBMC, MHC class II–matched or –mismatched tumor cell
lines, or 293 cells expressing DR2 molecules. Representa-
tive data from one such clone (F27TIL-T1) are shown in
Fig. 1 A. To determine the restriction elements used by T
cells, we tested T cell recognition in the presence or ab-
sence of specific Abs. As shown in Fig. 1 B, T cell reactiv-
ity against F27mel cells was specifically blocked by mAb
against HLA-DR, but not by mAb against HLA-DQ,
HLA-DP, or MHC class I molecules. HLA typing analysis
of F27mel cells indicated that only HLA-DR2 was ex-
pressed in tumor cells (unpublished data), which suggests
that CD4
 
  
 
F27TIL-T1 and other clones recognized a mu-
tated or unique tumor antigen presented by HLA-DR2.
Therefore, HLA-DR2 was selected as the restriction ele-
ment for the initial cDNA library screening.
Figure 1. Specific recognition of autologous melanoma cells by CD4 
F27TIL-T1. (A) Specific antitumor recognition of CD4  F27TIL-T1.
F27TIL-T1 recognized the autologous F27mel cells, but not EBV-B cell
lines and allogeneic melanoma cell lines or 293-derived cell lines. 888mel,
1011mel, 1195mel, 1280mel, 1297mel, and 1390mel shared the DR2
molecule with F27mel. T cell recognition was evaluated by GM-CSF re-
lease from CD4  F27TIL-T1. (B) HLA restriction of T cell recognition.
CD4  F27TIL-T1 cells were cocultured with autologous F27mel cells in
the presence or absence of various anti-MHC Abs. GM-CSF release was
determined after an 18-h incubation. T cell recognition of F27mel was
specifically blocked by an anti-DR Ab, but not by anti-MHC class I,
anti-DQ, or anti-DP Abs. 
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Identification of Mutated FN as a Tumor Antigen Recognized
by CD4
 
  
 
T Cells.
 
To isolate the gene encoding a tumor
antigen recognized by CD4
 
  
 
F27TIL-T1, we used a ge-
netic targeting expression system that has been successfully
used to identify several MHC class II–restricted tumor anti-
gens (7). This system uses a 293-based cell line as profes-
sional APC and an Ii-fused cDNA library. To generate
293IMDR2 cells expressing Ii, DMA, DMB, DRA, and
DRB1*1501, we first cloned HLA-DRB1*1501 cDNA
from the autologous F27mel cells into a pEF6/V5-His/
TOPO expression vector containing a blasticidin S resis-
tance gene. The cDNA sequence was confirmed to be that
of DRB1*1501. 293 cells stably expressing the other four
genes (Ii, DMA, DMB, and DRA, but not DRB1*1501),
were then transfected with the DR2-expressing plasmid
DNA. After selection with blasticidin S for 2 wk, the
293IMDR2 cell line was screened by FACS
 
® 
 
analysis using
a DR2-specific Ab, and further expanded for use as APC
for library screening.
We next constructed a cDNA library by fusing a target-
ing sequence of invariant chain to the 5
 
  
 
end of cDNAs de-
rived from F27mel tumor cells. As previously demon-
strated, this strategy will target Ii fusion proteins translated
from the Ii fusion library to the endosomal/lysosomal com-
partment for efficient antigen processing and presentation
to T cells (7). cDNA subpools with  100 cDNA clones
per pool were prepared. The F27mel cDNA library was
then introduced into 293IMDR2-expressing DMA, DMB,
Ii, DRA, and DRB1*1501 molecules. After screening a to-
tal of 2   105 cDNA clones, we identified five positive
cDNA pools that conferred T cell recognition by CD4 
F27TIL-T1 cells when transfected into 293IMDR2 cells.
The individual positive clones were then isolated from the
positive cDNA pools and tested for recognition by CD4 
F27TIL-T1 cells (Fig. 2 A). Evaluation of three other
CD4  T cell clones showed that they were capable of rec-
ognizing the same positive cDNA clone isolated from the
F27 cDNA library with F27TIL-T1 cells.
DNA sequencing analysis revealed that cDNA clone 3
contained a DNA fragment encoding the FN protein in-
volved in ECM formation, tumor transformation, and me-
tastasis (Fig. 2 B). All DNA sequences from five different
cDNA pools were identical to the published sequence with
the exception of one nucleotide A substitution for G at po-
sition 6435, based on the numbering of the published FN
sequence. These sequence data are available from Gen-
Bank/EMBL/DDBJ under accession no. NM-002026.
(16). This point mutation (G to A) at amino acid position
2053 was found in all positive cDNA clones, resulting in a
nonconservative substitution of Lys (positively charged res-
idue) for Glu (negatively charged residue) (Fig. 2 B). This
mutation was located in the region of type III repeats (II-
ICS) of cellular FN that is involved in the formation of
ECM (17). In addition, DNA sequences from the amplified
DNA fragments from autologous T cells or PBMC were
identical to the published wild-type sequence, suggesting
that this is a somatic mutation occurring in cancer cells.
Mutated Peptides Recognized by CD4  T Cells. To con-
firm that T cell recognition was restricted by HLA-DR2,
we transfected cDNA clone 3 into both 293IMDR2 and
293IMDR4 cells and then tested for recognition by CD4 
F27TIL-T1 cells. CD4  T cells recognized 293DR2 cells
transfected with the mutant FN cDNA, but not 293DR4
cells transfected with the wild-type FN cDNA nor
293DR4 cells transfected with the mutant FN cDNA (un-
published data), which suggests that T cell epitopes are lo-
cated in the region with a point mutation. To identify the
antigenic epitopes recognized by CD4  T cells, we made a
wild-type peptide and three overlapping 20-mer peptides
containing the mutated residue and tested their ability to
activate T cells. Two out of three mutant peptides were
recognized by CD4  F27TIL-T1 (Fig. 3 A). These two
mutated peptides shared 13 amino acids (MIFEKHGFR-
RTTPP), suggesting that this peptide sequence contained a
Figure 2. Screening of an Ii-cDNA library from RNA
of F27mel using CD4  F27TIL-T1 cells. (A) Identifica-
tion of positive cDNA clones encoding a tumor antigen
recognized by CD4  T cells. After the screening of 2  
105  Ii-cDNA fusion library clones generated from
F27mel RNA, positive cDNA pools were identified on
the basis of GM-CSF release from CD4  F27TIL-T1.
CD4  F27TIL-T1 recognized 293IMDR2 transfected
with the cDNA clone 3, but not with a control cDNA or
green fluorescent protein. (B) Schematic presentation of
FN protein and the position of the mutated amino acid.
Figure 3. Identification and characterization of peptides capable of stimu-
lating CD4  T cells. (A) Identification of peptides recognized by F27TIL-T1
cells. Two out of three overlapping peptides that contain the mutated
amino acid residue were recognized by T cells, whereas the corresponding
peptide with a wild-type residue failed to stimulate CD4  T cells. (B) De-
termination of peptide concentrations required for T cell recognition.
293IMDR2 cells were incubated with different concentrations of FN-P2
peptide for 90 min and then washed three times with T cell assay medium.
T cells were added to peptide-pulsed 293IMDR2 cells overnight. GM-
CSF release from T cells was determined with a GM-CSF ELISA kit.1401 Wang et al.
T cell epitope for T cell recognition. By contrast, T cells
failed to recognize the wild-type peptide, which lacked the
mutant residue but was otherwise identical to the mutated
peptides. Peptide titration experiments showed that T cell
recognition could readily be detected at a peptide concen-
tration of  500 nM (Fig. 3 B).
Mutant FN Disrupts FN Matrix Formation and Enhances the
Metastatic Potential of Tumor Cells. Because tumor cells are
a heterogeneous population, we conjectured that some
cells within the primary tumor cells might not contain the
FN mutation, whereas this G to A substitution should be
found in all metastatic lesions provided that the mutation
affects the metastatic potential of tumor cells. To test this
prediction, we generated 53 tumor cell clones by the limit-
ing dilution method from fresh tumor cells derived from
different metastatic lesions. After PCR amplification and
sequencing of genomic DNA, we found the presence of
the mutant FN gene in all tumor cell clones, which
strongly suggests that the mutation in FN plays a role in
subsequent tumor metastasis. By contrast, two control tu-
mor cell lines, 1143mel and 1195mel, contained the wild-
type FN allele exclusively. Representative data are shown
in Fig. 4 B.
Because FN plays a significant role in FN matrix forma-
tion (13, 18), we examined FN matrix formation in
F27mel as well as in 1143mel and 1195mel by staining with
an anti-FN Ab-9 Ab. As shown in Fig. 4 A, intense FN
staining was evident in 1143mel and 1195mel, but was sig-
nificantly reduced in F27mel cells. In contrast to 1143mel
and 1195mel cell lines, which only contained wild-type
FN, F27mel cells contained both wild-type and mutant FN
(Fig. 4 B). Thus, the point mutation in FN results in the
loss of ability to form FN matrices. We also stained for ex-
tracellular FN in tumor cell lines with three anti-FN Abs
(Ab-1, Ab-7, and Ab-8) that recognize epitopes located in
different regions of the FN molecule. The resulting stain-
ing patterns were either identical or similar to those ob-
tained with Ab-9 (Fig. 4 C), indicating that the point mu-
tation in FN did not alter its recognition by anti-FN Abs.
The loss of FN matrix formation has been implicated in
tumor transformation (12, 13). Tumor cells with metastatic
potential must migrate away from the primary tumor and
invade and implant in a distant site for the reestablishment
of a new tumor. Thus, the modulation of FN matrix for-
mation is a critical step in tumor metastasis (10). We postu-
lated that the loss or reduction of FN matrix formation in
F27mel cells may enhance tumor metastasis. To test this
possibility, we performed migration assays to measure the
ability of F27mel, 1143mel, and 1195mel tumor cells to
migrate through matrigel from one chamber containing
control medium to another chamber containing complete
growth medium. Interestingly, we found that relatively few
1143mel and 1195mel tumor cells with the wild-type FN
gene and normal FN matrix formation were capable of mi-
Figure 4. Loss of FN matrix formation in F27mel cells harboring a mutated FN. (A) Immunostaining of FN matrix of three melanoma cell lines
(1143mel, 1195mel, and F27mel) with Ab-9 anti-FN Ab. FN was detected by indirect immunofluorescence. Phase contrast and fluorescence images
were taken at  40. (B) Genomic DNA sequence analysis of FN in three melanoma cell lines. Genomic DNA fragments were amplified by FN-specific
primers. The PCR products were sequenced to identify mutated FN. (C) Comparison of immunostaining for FN matrix in 1143mel and F27mel cells
with different anti-FN (Ab-1, Ab-7, AB-8, and Ab-9) Abs that recognize epitopes in the different regions of FN. DAPI staining was used as controls for
cell density. Staining of FN matrix in 1143mel and F27mel cells with all four Abs showed these similar patterns: intensive staining of FN in 1143mel cells,
but little or weak staining in F27mel cells. 1143 and F27 stand for 1143mel and F27mel, respectively.1402 Role of a Mutated Fibronectin in ECM Formation and Metastasis
grating to the well containing the complete medium. In
contrast, the F27mel tumor cells readily migrated to the
well with complete medium in  20-fold higher numbers
than 1143mel and 1195mel (Fig. 5). These results demon-
strate that the FN mutation contributes to the subsequent
loss of FN matrix formation, leading to the enhanced met-
astatic potential of tumor cells.
Dominant-negative Effect on FN Matrix Formation. Be-
cause the interaction of FN with its receptor, an integrin
heterodimer ( 5 1), is important to ECM formation (12),
we next tested whether mutant FN may alter protein inter-
action between FN and integrin. We first immunoprecipi-
tated FN–integrin complexes with anti- 1 integrin Ab. As
shown in Fig. 6 A, similar amounts of integrin were pulled
down by anti- 1 integrin in the lysates of F27mel and
1143mel cells, but the amount of FN that formed com-
plexes with integrins in F27mel was much less than that in
1143mel tumor cells (Fig. 6 A). Because the Ab we used
could not distinguish wild-type from mutant FN proteins,
we also checked the total amount of FN in F27mel and
1143mel lysates. We found that the total amount of both
wild-type and mutant FN in F27mel was much lower than
that in 1143mel (Fig. 6 B). Thus, the overall difference in
the total amount of FN in the cell lysates of F27mel and
1143mel may account for the difference in the amount of
FN in the FN–integrin complexes immunoprecipitated
from F27mel and 1143mel.
To exclude the possibility that the low level of FN in
F27mel cells is due to low expression at the mRNA level,
we performed Northern blot analysis. Interestingly, the
mRNA level of FN in F27mel was much higher than in
1143mel cells, whereas actin probe hybridization showed
an equal amount of RNA loading (Fig. 6 C), which sug-
gests that the mutation in FN, rather than RNA expression
level, reduces the amount of FN and its complexes in
F27mel cells. In other words, mutant FN appears to have a
dominant-negative effect on FN matrix formation.
To determine whether the point mutation in FN is re-
sponsible for the loss of FN Ab staining in FN matrices
and the enhanced migration of tumor cells, we cloned
wild-type and mutant FN cDNAs from F27mel in a
pcDNA3.1Z expression vector (Fig. 7 A). The sequences
of both wild-type and mutant cDNA clones were con-
firmed by DNA sequencing analysis. These clones were
full-length cDNAs containing ED-A, ED-B, and IIICS
segments (Fig. 2 B), and the mutation (G to A) at amino
acid position 2053 was found in the mutated cDNA, but
otherwise was identical to the wild-type cDNA. With
these constructs, we were able to test our hypothesis that
the point mutation in FN was responsible for the ob-
served phenotypic changes. We transfected 1143mel with
pcDNA3-FN (wt) or pcDNA3-FN (mt) and selected them
in culture medium containing zeocin (250  g/ml). 12
clones expressing the wild-type FN construct were estab-
lished for 1143mel, 22 clones expressing mutant FN for
1143mel, and 9 clones for empty vector (control cell line).
The presence and expression of the mutant FN gene were
confirmed by reverse transcription–PCR and sequencing
analysis (unpublished data). FN staining was performed to
assess the effect of the transfected FN gene on matrix for-
mation and cell migration. Representative data from three
independent studies with different 1143mel cell clones sta-
bly expressing wild-type FN, mutant FN, or empty vector
are shown in Fig. 7 B. The similar staining patterns of FN
matrices were found for all three independent clones exam-
ined for each construct. The parental cell line 1143mel and
1143mel/pcDNA (empty vector) exhibited a comparable
staining intensity of FN matrices, whereas 1143mel/
Figure 5. The migratory capacity of F27mel compared with 1143mel
and 1195mel cells. The poorly metastatic tumor cell lines 1143mel and
1195mel have little or no capacity to migrate from the seeded chamber to
the chamber with complete medium, whereas F27mel readily migrated to
the chamber with complete medium. Cells were stained with crystal vio-
let, examined under a compound microscope, and photographed.
Figure 6. Western and North-
ern blot analyses of FN in differ-
ent tumor cell lines. (A) Tumor
cell lysates of 1143mel and
F27mel were first immunopre-
cipitated with an anti- 1 inte-
grin. The immunoprecipitated
proteins were separated on an
SDS-PAGE. After the transfer to
membrane, proteins were de-
tected with anti-FN or anti- 
integrin Abs. (B) Whole tumor
cell lysates of 1143mel and
F27mel cells were separated by
SDS-PAGE and analyzed with
the anti-FN Ab to determine the
total FN protein in the tumor
cell lysates. (C) Northern blot
analysis of total RNA isolated
from 1143mel and F27mel cells. Hybridization of blots with the probe of
FN detected an 8-kb band in 1143mel and F27mel tumor cells. An actin
probe was used to verify that equal amounts of total RNA were loaded
for each well. FN-specific RNA in F27mel cells was at least three- to
fourfold higher than that in 1143mel cells.1403 Wang et al.
pcDNA3-FN (wt) cells resulted in more intense staining.
By contrast, 1143mel cells stably expressing pcDNA3-FN
(mt) showed little or no staining of FN matrices compared
with other cell lines/clones containing wild-type FN, dem-
onstrating that expression of mutant FN in 1143mel cells
abolishes immunostaining for endogenous wild-type FN/
ectopic mutant FN in the matrix assembly of tumor cells.
We next evaluated the migratory ability of these cell
lines expressing wild-type or mutant FN. As shown in Fig.
8 A, 1143mel, 1143mel/pcDNA3-FN (wt), and 1143mel/
pcDNA3 cells displayed little or no migration in a matrigel
assay. However, 1143mel/pcDNA3-FN (mt) cells greatly
gained the ability to migrate from one chamber containing
control medium to another chamber containing growth
Figure 7. Determination of the FN mutation responsi-
ble for the dominant-negative phenotype of FN matrix
formation. (A) PCR products (7,114 bp) of full-length FN
were obtained after amplification using a pair of primers
and the first strand cDNA generated from F27mel tumor
RNA. Cloning of both wild-type and mutant FN in a
pcDNA3 expression vector. Wild-type and mutant FN
were verified by DNA sequencing. (B) Immunostaining of
FN matrices in 1143mel and derivative cell lines expressing
wild-type FN, mutant FN, or empty vector. DAPI stain-
ing was used as a control for cell density.
Figure 8. Mutant FN is responsible for the enhanced metastatic potential of tumor cells. (A) Stable expression of mutant FN in 1143mel cells resulted
in enhanced migration ability in matrigel assays. Untreated 1143mel and 1143mel cells expressing wild-type FN or empty vector showed little or no mi-
gration from one chamber to another containing complete medium. (B) Migration assays were repeated in three independent experiments, each comprising
four sets of independent 1143mel-derived tumor cell clones expressing wild-type FN, mutant FN, or empty vector. The numbers of cells that migrated
to the bottomed chamber containing complete medium were counted in four representative fields (20 ) per chamber. The data are presented as means
of the number of cells migrated and standard deviations. A P value of 0.0007 was obtained from Student’s t test for the group expressing mutant FN and
any other groups.1404 Role of a Mutated Fibronectin in ECM Formation and Metastasis
medium, indicating that the mutant FN enhances the met-
astatic potential of tumor cells. To rule out clonal varia-
tion, we repeated similar experiments with four sets of in-
dependent tumor cell clones expressing wild-type FN,
mutant FN, or empty vector. In Fig. 8 B, a summary of
results obtained from these experiments shows that all tu-
mor cell clones expressing mutant FN had an increased
ability to migrate compared with cell clones expressing
wild-type FN or an empty vector. The number of migrat-
ing cells in 1143mel/pcDNA-FN (mt) clones was at least
fourfold higher than that of other groups that express ei-
ther wild-type FN or empty vector. The P value for sig-
nificant difference is 0.0007 among the two comparison
groups of cell clones expressing mutant FN and other cell
clones expressing either wild-type FN or empty vector.
There were no statistically significant differences among
groups of parental 1143mel and its derivative clones ex-
pressing wild-type or empty vector. These results indicate
that expression of mutant FN greatly enhances the migra-
tory capacity of tumor cells.
Discussion
Because of the importance of CD4  T cells in antitumor
immunity, much effort has been directed toward identify-
ing MHC class II–restricted tumor antigens. So far, only
DR1- or DR4-restricted tumor antigens have been identi-
fied with tumor-reactive CD4  T cells established from
TIL (3, 19). Due to the polymorphic properties of MHC
class II molecules, DR1 or DR4 expression accounts for
15–20% of the population (20). Identification of tumor an-
tigens presented by other relatively dominant alleles such as
DR2, DR3, or R7 (each accounting for 20–25% of the
population) remains critically important for the develop-
ment of effective vaccines by recruiting both CD4  and
CD8  T cells. Indeed, T cell recognition of potentially
shared tumor antigens presented by DR2 (DR 1*1501)
molecules has been reported (21), but the identity of such
antigens remains unknown.
In this study, we identified a novel mutated form of FN
as a tumor antigen recognized by CD4  F27TIL using a
genetic targeting expression approach. The findings pre-
sented in this study strongly suggest that tumor-reactive
CD4  T cells may play a significant role in eliminating
metastatic cancer cells. FN is a gene product critical for
ECM formation and indispensable for vertebrate embryo-
genesis (22). FN forms a complex with its receptor inte-
grins ( 5 1) for the initiation of ECM formation. The loss
of capacity to form an FN containing ECM has been sug-
gested to be a feature of the transformed phenotype of can-
cer cells, and restoration of ECM formation correlates with
the reduced malignancy of cancer cells (11–13). Recently,
several groups, using microarray technology, demonstrated
a link between FN expression at the RNA level and tumor
metastasis (10, 23, 24). Interestingly, our Northern blot
data are consistent with these published results, which show
that FN mRNA is approximately fourfold higher in meta-
static versus poorly metastatic tumor cells. However, the
protein level of FN in highly metastatic tumor cells
(F27mel) was much lower than in poorly metastatic tumor
cells (1143mel). The reduced FN protein in metastatic tu-
mor cells was associated with the significant reduction of
FN matrix formation. Because introduction of the mutant
FN into tumor cells expressing wild-type FN resulted in a
significant loss of FN matrix formation whereas the empty
vector did not, we believed that the point mutation, which
resulted in the substitution of Lys for Glu, was responsible
for the observed phenotype. More importantly, we dem-
onstrated that this point mutation in FN converted poorly
metastatic tumor cells to highly metastatic ones. To our
knowledge, this is the first report showing that mutated FN
directly affects extracellular FN matrix formation and
therefore enhances the metastatic potential of tumor cells.
Our results indicate that CD4  F27TIL-T1 cells recog-
nized a mutated FN presented by DR2 molecules. Al-
though several mutated forms of proteins such as CDC27
(nuclear protein) involved in cell cycle regulation, triose-
phosphate isomerase (cytosolic protein) required for energy
production, and the secretory fusion protein LDFP (LDLR
and FUT fusion protein) resulting from chromosomal rear-
rangement have been identified as class II–restricted tumor
antigens, they are presented by either DR1 or DR4 mole-
cules. Of particular interest is that the majority of MHC
class II–restricted tumor antigens identified by tumor-reac-
tive CD4  T cells derived from cancer patients are mutated
or fusion proteins. By contrast, the majority of the MHC
class I–restricted tumor antigens recognized by CD8 
CTLs are nonmutated self-antigens (2). All of the known
MHC class I–restricted human melanoma antigens, such as
tyrosinase, gp100, MAGE-3, and NY-ESO-1, also con-
tained CD4  T cell epitopes, but they were identified ei-
ther by the stimulation of human PBMC with dendritic
cells pulsed with peptides or proteins (25–29), or by the use
of HLA-DR4 transgenic mice (30, 31). None, with the ex-
ception of tyrosinase, were identified by tumor-reactive
CD4  T cells derived from patients, although the mecha-
nism responsible for this is not understood. Because both
animal and human studies indicate that CD4  T cells play a
central role in initiating and maintaining host immune re-
sponses against cancer, the presence of such self-reactive
CD4  T cells may cause self-tissue destruction. Self-anti-
gens such as gp100- and tyrosinase-specific CD4  T cells
could be induced after the stimulation of PBMCs with
peptides in vitro. However, such T cells exhibited a rela-
tively low affinity for MHC–peptide complexes compared
with T cells specific for mutated tumor antigens and re-
quired a high concentration of peptide for T cell recogni-
tion (31, 32).
Although vaccines containing nonmutated, shared class
II–restricted tumor antigens may be useful in a broad cov-
erage of cancer patients, mutated tumor antigens may have
a limited clinical application. Nonetheless, several MHC
class II–restricted mutated murine tumor antigens have
been identified by a biochemical approach (33, 34). Immu-
nization with T helper peptides from viral or the mutated1405 Wang et al.
proteins can effectively reject MHC class II–negative tu-
mor cells, which suggests the importance of CD4  T cell
response in antitumor immunity (34–37). Moreover, in ad-
dition to providing help for CD8  T cells (38), CD4  T
cells may play a far broader role in orchestrating the host
response to tumor (39) and autoimmune diseases (40). Ad-
ditional definition of MHC class II–restricted antigens may
provide new opportunities for developing effective immu-
notherapy against cancer.
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